ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
FTSE 100
8,320.76
0.43%
Dow Jones
42,313.00
0.33%
Gold vs US Dollar
2,651.62
-0.78%
Brent Oil
71.96
1.42%
Bitcoin
65,803.29
0.95%
Pepperstone
Advertisement
Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Incyte Corporation (INCY)

  7. Incyte Corporation (INCY) News

Incyte (INCY)

Incyte Corporation
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:INCY
DateTimeSourceHeadlineSymbolCompany
26/09/202401:20Business WirePlusieurs présentations de données de dernière minute dérivées du portefeuille dermatologique d’Incyte vont avoir lieu à l’occasion du Congrès 2024 de l’European Academy of Dermatology and Venereology (EADV)NASDAQ:INCYIncyte Corporation
26/09/202401:20Business WireMehrere brandaktuelle Datenpräsentationen aus dem Dermatologie-Portfolio von Incyte werden auf dem Kongress der Europäischen Akademie für Dermatologie und Venerologie (EADV) 2024 vorgestelltNASDAQ:INCYIncyte Corporation
25/09/202412:00Business WireMultiple Late-Breaking Data Presentations from Incyte’s Dermatology Portfolio will be Featured at the European Academy of Dermatology and Venereology (EADV) 2024 CongressNASDAQ:INCYIncyte Corporation
18/09/202422:15PR Newswire (US)Incyte and Syndax Announce New England Journal of Medicine Publication of Data from Pivotal AGAVE-201 Trial of Niktimvo™ (axatilimab-csfr) in Chronic Graft-Versus-Host DiseaseNASDAQ:INCYIncyte Corporation
16/09/202418:25Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:INCYIncyte Corporation
16/09/202418:24Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:INCYIncyte Corporation
15/09/202423:36Business WireRetifanlimab (Zynyz®) von Incyte verlängert progressionsfreies Überleben bei Patienten mit Plattenepithel-Analkarzinom (SCAC) – Datenpräsentation beim ESMO Presidential Symposium 2024NASDAQ:INCYIncyte Corporation
15/09/202406:34Business WireIncyte’s CDK2 Inhibitor INCB123667 zeigt vielversprechende Anzeichen von klinischer Wirkung bei Patienten mit soliden Tumoren in fortgeschrittenem StadiumNASDAQ:INCYIncyte Corporation
15/09/202406:34Business WireINCB123667, l'inhibiteur de la CDK2 d'Incyte, montre des signes prometteurs d'activité clinique chez des patientes atteintes de tumeurs solides avancées, notamment le cancer de l'ovaireNASDAQ:INCYIncyte Corporation
15/09/202405:48Business WireLe rétifanlimab (Zynyz®) d’Incyte prolonge la survie sans progression chez les patients atteints de carcinome épidermoïde du canal anal (SCAC) ; des données ont été présentées lors du Symposium présidentiel de l’ESMO 2024NASDAQ:INCYIncyte Corporation
14/09/202417:45Business WireIncyte’s CDK2 Inhibitor INCB123667 Shows Promising Evidence of Clinical Activity in Patients with Advanced Solid Tumors, Notably Ovarian CancerNASDAQ:INCYIncyte Corporation
14/09/202415:30Business WireIncyte’s Retifanlimab (Zynyz®) Extends Progression-Free Survival in Patients with Squamous Cell Anal Carcinoma (SCAC); Data Featured at ESMO 2024 Presidential SymposiumNASDAQ:INCYIncyte Corporation
13/09/202421:06Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:INCYIncyte Corporation
12/09/202421:17Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:INCYIncyte Corporation
09/09/202421:30Business WireIncyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:INCYIncyte Corporation
21/08/202421:49Business WireIncyte präsentiert bahnbrechende Phase 3-Ergebnisse für Retifanlimab (Zynyz®) und erste Daten aus Phase 1 des CDK2-Inhibitor-Programms auf dem Kongress der European Society of Medical Oncology (ESMO) 2024NASDAQ:INCYIncyte Corporation
21/08/202421:49Business WireIncyte présentera les résultats de la phase 3 de Retifanlimab (Zynyz®) et les données initiales du programme d'inhibiteurs de CDK2 de phase 1 à l'édition 2024 du Congrès de la Société européenne d'oncologie médicale (ESMO)NASDAQ:INCYIncyte Corporation
21/08/202416:40Business WireIncyte to Present Late-Breaking Phase 3 Results for Retifanlimab (Zynyz®) and Initial Data from Phase 1 CDK2 Inhibitor Program at the European Society of Medical Oncology (ESMO) Congress 2024NASDAQ:INCYIncyte Corporation
16/08/202410:59Business WireIncyte gibt positive Topline-Ergebnisse der Pivotalstudie mit Tafasitamab (Monjuvi®) bei rezidiviertem oder refraktärem follikulärem Lymphom bekanntNASDAQ:INCYIncyte Corporation
16/08/202410:46Business WireIncyte annonce des résultats positifs de l'étude pivot sur le tafasitamab (Monjuvi®) dans le lymphome folliculaire récidivant ou réfractaireNASDAQ:INCYIncyte Corporation
15/08/202421:30Business WireIncyte Announces Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi®) in Relapsed or Refractory Follicular LymphomaNASDAQ:INCYIncyte Corporation
15/08/202421:15Business WireIncyte und Syndax melden FDA-Zulassung von Niktimvo™ (Axatilimab-csfr) zur Behandlung der chronischen Graft-versus-Host-Krankheit (GvHD)NASDAQ:INCYIncyte Corporation
15/08/202411:26Business WireIncyte et Syndax annoncent l’approbation par la FDA américaine de Niktimvo™ (axatilimab-csfr) pour le traitement de la maladie chronique du greffon contre l’hôte (GVHD)NASDAQ:INCYIncyte Corporation
14/08/202422:34Business WireIncyte and Syndax Announce U.S. FDA Approval of Niktimvo™ (axatilimab-csfr) for the Treatment of Chronic Graft-Versus-Host Disease (GVHD)NASDAQ:INCYIncyte Corporation
14/08/202420:37Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:INCYIncyte Corporation
13/08/202413:00Business WireIncyte to Present at Upcoming Investor ConferencesNASDAQ:INCYIncyte Corporation
12/08/202421:39Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:INCYIncyte Corporation
07/08/202422:00Business WireIncyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:INCYIncyte Corporation
30/07/202412:15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:INCYIncyte Corporation
30/07/202412:00Business WireIncyte Reports 2024 Second Quarter Financial Results and Provides Updates on Key Clinical ProgramsNASDAQ:INCYIncyte Corporation
 Showing the most relevant articles for your search:NASDAQ:INCY

Your Recent History

NASDAQ
FXENP
USOTC
QRNNF
Aurizon (PK)
NASDAQ
AMCP
NYSE
ANVS
Annovis Bio
LSE
KLN
Kellan Group
TG
NADQ
Amundi Nasdaq100 II UCIT...
Delayed Upgrade Clock
    ADVFN Logo
    InvestorsHub

    United Kingdom
    Company
    Business
    Popular
    Get The App
    App Store
    Google Play

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved